Table 1.

Clinical characteristics and expression of CLASP2 and EMT markers mRNA

Variables	Patients (n)	Progression within 2 years
		No (n)	Yes (n)	P
Total (%)	102	68	34
Gender
Male	72	52	20	0.11
Female	30	16	14
Age(years)
< 60	38	27	11	0.61
> 60	64	41	23
Intravesical instillation
Immediate	29	22	7	0.31
Maintenance	73	46	27
Tumor stage
Ta	34	25	9	0.41
T1	68	43	25
Tumor grade
G1	33	26	7	0.04
G2	49	33	16
G3	20	9	11
Concomitant CIS
Yes	3	1	2	0.26
No	99	67	32
Tumor size (cm)
< 3	59	44	15	0.07
> 3	43	24	19
Multiplicity
Single	44	34	10	0.06
Multiple	58	34	24
CLASP2 mRNA (tumor)
High	30	6	24	<0.01
Low	72	62	10
CLASP2 mRNA (urine)
High	55	24	31	< 0.01
Low	47	44	3
E-cadherin mRNA (tumor)
High	62	52	10	< 0.01
Low	40	16	24
E-cadherin mRNA (urine)
High	60	54	6	< 0.01
Low	42	14	28
Vimentin mRNA (tumor)
High	55	31	24	0.16
Low	47	37	10
Vimentin mRNA (urine)
High	62	36	26	0.03
Low	40	32	8